UNIVERSITY OF BIRMINGHAM

University of Birmingham Research at Birmingham

Barriers to administering non-oral formulations in a paediatric population

Venables, Rebecca; Batchelor, Hannah; Stirling, Heather; Marriott, John

[Link to publication on Research at Birmingham portal](#)

1   Dr Rebecca Hayley Venables

2   +4401782733573

3   r.h.venables@keele.ac.uk

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Dr Rebecca Hayley Venables

Abstract

Acceptability of medicines for children is a challenge, yet critical to ensure adherence to treatment. There is very little literature on formulation factors that influence acceptability of medicines, particularly in the domiciliary environment. This pragmatic study was conducted at University Hospital Coventry and Warwickshire (UHCW) with the aim of identifying the prevalence and nature of oral formulation-related barriers to medicines administration in children suffering from long-term conditions.

This study used semi-structured face-to-face interviews with 221 parents/carers of children (0-18 years) and 57 young people (12-18years).

Results showed significant medicines refusal and manipulation in the domiciliary environment. Nearly one-third (71/232) of respondents reported medicines refusal. This was associated significantly with the age of child ($p=0.016$), socioeconomic status (IMD 2010 score)($p=0.002$), taste ($p<0.001$), texture ($p=0.017$), and volume (of liquid/powder) or quantity (of solid dosage form) ($p<0.001$). 29%(74/252) of respondents reported manipulating medicines. P-values are based on multivariable statistical analysis models.

This study has indicated that formulations prescribed to children with chronic conditions are not meeting the needs of a significant number of patients based on self-report. Age-appropriate medicines are required to provide suitable dose units with an acceptable taste for children. This study should aid pharmaceutical companies to prioritise paediatric formulation work.

1 Introduction

Approximately 200 million prescriptions are issued annually for children and young people in the UK (Costello et al., 2004). Previous studies have investigated medicines adherence in children, however these have not explored potential barriers to adherence in the domiciliary setting. In this paper, barriers are defined as obstacles that could result in non-adherence of medicines (e.g. forgetting, refuse, hard to swallow, etc.).

There is a paucity of studies investigating barriers to medicines administration arising from oral formulations (particularly those related to organoleptic and physical properties) in children with chronic conditions. Those studies reported previously are limited to specific disease groups, e.g. antiretroviral medicines in Human Immunodeficiency Virus (HIV) (Boni et al., 2000; Gibb et al., 2003; Goode et al., 2003; Marhefka et al., 2004; Pontali et al., 2001; Wrubel et al., 2005). Further studies compare the acceptance and flavour preferences of a spectrum of drugs from one class (e.g. antibiotics) using a "one-off" taste test method, commonly with the aid of a visual analogue scale (VAS) most often in healthy children or adults (Bagger-Sjöbäck and Bondesson, 1989; Chan et al., 1997; Cohen et al., 2009; El-Chaar et al., 1996; Samulak et al., 1996; Toscani et al., 2000).

The present study targets a large paediatric population suffering from different chronic conditions.

The palatability of paediatric medicines is one of the most important formulation factors with potential to influence adherence to therapeutic regimens and outcomes (Salunke et al., 2011). It has been demonstrated that making medications more pleasing to the child can have a positive effect on compliance (Winnick et al., 2005). Refusal of a formulation was defined in the present study as, 'complete omission of a dose by intent on at least one occasion, including spitting the dose back out, and/or closing the mouth' and medicine manipulation was defined as 'a medicine physically adapted to facilitate medicines administration or for the purpose of giving a specific dose.'

68 The importance and incentive to study the palatability of paediatric formulations was discussed in

69 the reflection paper (EMEA, 2006) and endorsed in the latest European Paediatric guideline on

70 pharmaceutical development of formulations for paediatric use (EMA, 2013).

71 The aims of the present study were (i) to identify the prevalence and nature of oral formulation-

72 related barriers to medicines administration in children suffering from long-term conditions in a

73 domiciliary environment; (ii) to identify the prevalence of children refusing formulations and also

74 determine which formulation factors influenced oral medicines refusal and (iii) to evaluate the

75 prevalence and nature of oral medicines manipulation by parents, carers and children in the

76 domiciliary environment.

2   Materials and Methods

2.1   Data collection tool

79 Understanding formulation acceptability in a domicilliary environment requries the use of

80 alternative means of data collection compared to in-patient studies. A semi-structured interview was

81 selected for this study to obtain the appropriate balance in data collection and subsequent analysis

82 (Malim and Birch, 1996). During a semi-structured interview, the interviewer is able to show

83 empathy and alter phrasing of questions in order to elicit detailed and considered responses from

84 participants; these benefits have been previously shown to provide more detailed outputs (Gillham,

85 2000) and an increased response rate (Chambers, 2000) compared to paper-based questionnaires.

86 A multidisciplinary research team (Professor in Clinical Pharmacy, paediatric consultant and

87 pharmacist) generated an outline of key problems with administering oral formulations to children;

88 these issues were refined via four focus groups with healthcare professionals at the University

89 Hospital Coventry and Warwickshire (UHCW) and Birmingham Children's Hospital (BCH). The data

90 collected, in addition to self-report methodologies referenced in published studies (Medical

91 Adherence Measure - MAM (Ingerski et al., 2009; Zelikovsky et al., 2008), Treatment Interview

92 Protocol - TIP (Marhefka et al., 2004), Pediatric AIDS Clinical Trials Group PACTG questionnaire

93 (NIAID) and Morisky Scales (Morisky et al., 2008; Morisky et al., 1986) were used to inform the

94 design of the self-report semi-structured interview tool. The Young Persons Advisory Group (YPAG)

95 at Birmingham Children's Hospital (n=12 members) reviewed the tool to ensure that it was age

96 appropriate.

97 The 13-item self-report tool (Supplementary File 1) used in the semi-structured interviews was

98 designed to collect data exploring medicines adherence including medicines refusal (see Q5 in

99 Supplementary File 1), medicines manipulation (see Q3a in Supplementary File 1) and barriers to

100 medicines administration (see Q3b in Supplementary File 1) in parents, carers and children

101 themselves. Open questions were used to elicit reasons for medicines refusal to avoid bias.

102 A semi-structured interview was conducted by a single researcher (post-graduate pharmacist (RV) -

103 not previously known to the patients) to minimise variation in approach and the responses were

104 entered manually onto a structured data record during each interview. The interviews (maximum

105 duration of 45 minutes) were conducted in a private area at the paediatric outpatients department

106 at UHCW at times scheduled to coincide with routine clinical appointments. Ethical approval was

107 granted by the South Birmingham REC and informed consent was obtained for all participants.

108 Participants were invited to provide demographic information in order to generate an Index of

109 Multiple Deprivation 2010 (IMD 2010) score.

110

111 ## 2.2 Qualitative Analysis

112 Themes were identified using a frame-work analysis approach to form a coding spine. Thematic

113 content analysis (Pope et al., 2000) was used to identify and group common themes,relating to

114 medicines administration. Qualitative data was analysed using NVivo 8 software (QSR International).

2.3 Statistical Analysis

Statistical analysis was conducted using generalised estimating equations to explore the relationship between independent variables (e.g. child age, IMD score, formulation type) and dependent variables with binary outcomes (Refusal or Manipulation).

Patient, participant and data on formulations were converted into categorical variables (see Tables 2 & 3).

Data analysis was performed on an individual medicine level facilitating comparisons between medicine specific variables (e.g. different medicine groups and formulations), which are not possible at a patient level. In order to account possible non-independence of data owing to any response correlation to medicines taken by an individual, univariable generalised estimating equations were used. The univariable analysis did not control for potential relationships between independent variables therefore multivariable analysis was also conducted using the combination of independent variables found to be significant ($p<0.05$) for the dependent variables in the univariable model (medicines refusal, medicines manipulations). This generated Odds Ratios, 95% confidence intervals and associated p values. The data was analysed using SPSS version 20 software (IBM).

2.4 Study Setting and Study Participants

A pragmatic approach was employed to identify and recruit participants resulting in a total of 1559 study invitation letters being posted to patients (via their parent/carer) due to attend follow-up paediatric clinics (1448/1559) or handed out on the paediatric wards (111/1559) at UHCW. Study interviews were conducted with parents or carers (if legal guardians) of children or young people, or with young people directly. The opportunity to assent and participate alone was given to 12-16 year olds providing parent or carer consent was also obtained. Young people over 16 years of age were permitted to consent alone and encouraged to discuss the study with a parent or legal guardian before providing consent. It was necessary to include young people (those over 12 years of age),

140   where appropriate as this sub-population reported increased personal management of their

141   medicines administration. Parents or carers views were more useful for younger children where they

142   may not have the cognitive capability to participate alone.

143   Age-appropriate study information was provided to potential participants at least 24 hours before

144   asking for participation in the study.

145   A total of 191 general and speciality outpatient clinics were targeted covering a wide range of

146   chronic conditions (e.g. epilepsy, cystic fibrosis, neoplasms, cardiac disorders, endocrine disorders,

147   tuberculosis, HIV, renal diseases, rheumatological diseases and survivors of neonatal intensive care).

148   It should be noted that not all patients in clinics were prescribed medicines, therefore not all

149   patients were eligible for study inclusion. There was a scheduled approach to accessing patients at

150   these clinics on a rotating basis to ensure wide coverage of the target patient population. UHCW is a

151   teaching hospital with three age-banded paediatric wards. All have a wide range of paediatric

152   patients without specialism. Inpatients from all three paediatric wards at UHCW were included at

153   the recruitment phase to minimise the risk of missing eligible patients who were hospitalised during

154   the study period. The recruitment phase lasted 15 months from November 2010 to February 2012.

2.4.1 Inclusion criteria

156   The study included children (aged 0- <18 years) with chronic conditions and their parents or carers.

157   Age bandings were based on pre-school; school-age and adolescents to match cognitive function.

158   Patients were eligible for inclusion if they had been taking prescribed medication for a chronic

159   condition for at least one month prior to their outpatient appointment.

3   Results

161   A total of 280 participants consented to the study (Figure 1). Interviews were completed with 221

162   parents/carers and 57 young people (in the presence of a parent/carer (n=42), in the absence of a

163   parent/carer (n=15)). In total, (91%) 252/278 of the children included were prescribed at least one

164 oral formulation. The remaining 26 patients were not prescribed any oral formulations, only non-

165 oral formulations. The data from these patients was analysed separately and is not included in the

166 subsequent analyses.

167

3.1 Participant demographics and medicines

169 The 252 children receiving oral formulations were categorised into three age groups: 0-4 years

170 (n=92), 5-11 years (n=93) and 12-18 years (n=67), see Table 1 for the frequency of oral formulation

171 types prescribed.

172 **Table 1: The frequency of oral formulation types prescribed across child age ranges 0-4y, 4-12y and**
173 **12-18y**

Age Group	0-4 years (n=92)	5-11 years (n=93)	12-18 years (n=67)	Total in 252 children
Liquids	130	86	36	252
Tablets or capsules	20	61	96	177
Other (granules, powders, soluble tablets and melts)	49	47	17	113
Totals	199	194	149	542

174 n represents the number of children in each age range (0-4, 5-11 and 12-18 years)

175 In total, 542 oral formulations were prescribed across the cohort (with the number of oral

176 formulations prescribed to each patient ranging from 1 to 8).

177 Of these oral formulations, 8% (41/542) were identified as 'Specials' (i.e. unlicensed formulations

178 prepared under the terms of a Marketing Authorisation, granted by the Medicines and Healthcare

179 products Regulatory Agency) (MHRA).

180

3.2 Medicines refusal

182 In total, 232/252 of participants answered the question (Q5 see Supplementary File 1) about the

183 refusal of formulations, resulting in data on 436/542 of formulations. Of these, 8% (44/542) of

184 formulations were administered via nasogastric or percutaneous endoscopic gastrostomy tubes and

185 medicine refusal was not permitted, therefore data is unavailable on these medications for 10

186   patients. The medicines refusal question was not delivered to a further 10 participants owing to time

187   constraints. Almost one third (71/232) of respondents reported medicines refusal on at least one

188   occasion; multivariable statistical analysis was conducted on this data set. The results are reported in

189   Table 2.

190   **Table 2: Multivariable analysis results: Reports of medicines refusal on at least one occasion**

	Odds Ratio (95% CI)	p Value
Age of child at Interview		**0.016***
0-4 years	1	
5-11 years	0.42 (0.19 - 0.89)	0.024*
12-18 years	1.31 (0.54 - 3.20)	0.554
IMD 2010 score		**0.002***
<11.5	1	
11.5-19.8	1.32 (0.49-3.51)	0.584
19.9-31.9	3.19 (1.37-7.43)	0.007*
32+	4.75 (2.02-11.18)	<0.001*
Formulation type		**0.336**
Liquid	1	
Capsules and Tablets	0.59 (0.27-1.30)	0.193
Other (granules, powders, soluble tablets and melts)	0.64 (0.30-1.38)	0.254
Problem with taste		**<0.001***
No	1	
Yes	3.82 (2.11-6.92)	<0.001*
Problem with texture		**0.017***
No	1	
Yes	3.38 (1.24-9.22)	0.017*
Problem with volume or quantity		**<0.001***
No	1	
Yes	12.79 (4.41-37.12)	<0.001*
Problem with smell		**0.776**
No	1	
Yes	1.24 (0.28-5.46)	0.776

191   p values marked with * identify statistically significant results (p<0.05).

192   The age of child at interview was found to be a significant predictor of refusal, with children aged

193   between 5-11 the least likely to have refused medicines (OR=0.42, relative to the 0-4 year group;

194   95% CI: 0.19-0.89; p=0.024). However, no significant difference was detected between the likelihood

195   of medicines refusal in the 12-18 years group, relative to the 0-4 years group (OR=1.31; 95% CI: 0.54-

196   3.20; p=0.554). The likelihood of medicines refusal was found to increase significantly (p=0.002)

across the IMD score groups, peaking at an odds ratio of 4.75 (95% CI: 2.02-11.18; p<0.001) in the
most deprived patient group (IMD=32+) relative to the least deprived (IMD<11.5).

A range of medicines related factors were also found to be associated with refusal in children.
Patients who had problems with the volume or quantity of medication were considerably more likely
to have a history of medicines refusal (OR=12.79; 95% CI: 4.41-37.12; p<0.001), with issues with
either taste (OR=3.82; 95% CI: 2.11-6.92; p<0.001) or texture (OR=3.38; 95% CI: 1.24-9.22; p=0.017)
also being significant predictors of refusal. However, after accounting for these factors, there was no
significant evidence that either the smell (p=0.776), or the type of formulation (p=0.336), had any
impact on refusal rates.

3.3 Medicines manipulation

Almost one third (74/252) of respondents reported manipulating formulations.

In total, 19% (94/499) of formulations were manipulated. Of these, the majority (93%, 87/94) were
reported to be manipulated 'always' (i.e. prior to every dose administration).

Of the medicine manipulations reported, 26% (24/94) were performed for the purpose of
administering a specific dose (e.g. one quarter of a tablet), whilst the majority of medicine
manipulations, 79% (74/94) were performed to facilitate medicines administration (e.g. mixed into
foodstuffs). Omeprazole soluble tablets, macrogol 3350 oral powder, co-trimoxazole tablets and
mercaptopurine tablets were most often manipulated (by at least 40% of users). For over three
quarters (78% 7/9) of children prescribed omeprazole soluble tablets, medicines manipulation was
reported.

The age of the child at the interview was found to be a significant predictor of the reporting of
medicines manipulation (p=0.005). Reports became progressively less likely with increasing age, with
Odds Ratios of 0.29 (95% CI: 0.13-0.67; p=0.004) in the 5-11 year age group, and 0.18 (95% CI: 0.06-
0.59; p=0.005) in the 12-18 year age group, relative to patients in the 0-4 year group.

222   The type of formulation was also associated significantly with reporting of medicines manipulation

223   (p<0.001), with tablets and capsules (OR: 9.66; 95% CI: 3.48-26.87; p<0.001) and other formulations

224   (granules, powders, soluble tablets and melts) (OR: 23.97; 95% CI: 9.14-62.84; p<0.001) both more

225   likely to be manipulated than liquids. Manipulation was also found to be significantly more likely to

226   be reported where patients had problems with either the size (OR: 4.52; 95% CI: 1.37-14.90;

227   p=0.013) or the texture (OR: 3.15; 95% CI: 1.39-7.14; p=0.006) of the medicines. In cases where the

228   child had partial responsibility for the administration of a medicine, significantly lower rates of

229   manipulation were reported, relative to where the parent or guardian was solely responsible (OR:

230   0.28; 95% CI: 0.10-0.81; p=0.019). A similar effect was observed where the child was totally

231   responsible for medicines administration, although this was not statistically significant (OR: 0.22;

232   95% CI: 0.02-1.94; p=0.171). The results are reported in Table 3.

233   **Table 3: Multivariable analysis results: Reports of medicines manipulation**

	Odds Ratio (95% CI)	P Value
Age of child at Interview		**0.005***
0-4 years	1	
5-11 years	0.29 (0.13-0.67)	0.004*
12-18 years	0.18 (0.06-0.59)	0.005*
Is English first language of participant		**0.085**
Yes	1	
No	0.26 (0.06-1.20)	0.085
Formulation type		**<0.001***
Liquid	1	
Tablets and Capsules	9.66 (3.48-26.87)	<0.001*
Other (granules, powders, soluble tablets and melts)	23.97 (9.14-62.84)	<0.001*
Problem with size of dosage form or aversion to/difficulty swallowing dosage form		**0.013***
No	1	
Yes	4.52 (1.37-14.90)	0.013*
Problem with texture		**0.006***
No	1	
Yes	3.15 (1.39-7.14)	0.006*
Problem related to other formulation and administration problems		**0.206**
No	1	
Yes	1.89 (0.70-5.08)	0.206

11

Who is responsible for medicines administration		0.049*
Parent/Guardian	1	
Child plus Parent/Guardian	0.28 (0.10-0.81)	0.019*
Child	0.22 (0.02-1.94)	0.171
Problem with volume or quantity		**0.157**
No	1	
Yes	2.17 (0.74-6.35)	0.157
Frequency of dosing		**0.404**
1x daily	1	
2x daily	0.70 (0.34-1.45)	0.345
≥3x daily	0.20 (0.03-1.46)	0.113
<1x daily (not including medicines prescribed on a 'when required' basis)	0.76 (0.23-2.46)	0.647

234   p values marked with * identify statistically significant results (p<0.05).

235

3.4 Barriers to oral medicines administration

3.4.1 Taste

Taste was the most commonly reported barrier to medicines administration affecting 35% (188/542) of all prescribed oral formulations, and associated with 64% (54/85) of formulations that were refused.

Formulations with the highest incidence of taste issues were ranitidine liquid (82%; 9/11 children), prednisolone soluble tablets (81%; 13/16 children) and trimethoprim liquid (75%; 6/8 children) of total users. However, taste issues were reported for at least 50% of children prescribed other common drugs (lactulose liquid, macrogol 3350 oral powder sachets, co-trimoxazole tablets, sodium valproate liquid, levetiracetam liquid, penicillin liquid, ibuprofen liquid and prednisolone tablets). See Figure 2 for reported taste problems.

3.4.2 Texture

Texture was reported to affect 8% (42/542) of all prescribed oral formulations, and was a significant predictor of medicines refusal. Co-trimoxazole liquid (38%), omeprazole soluble tablets (33%) and lactulose liquid (25%) were most commonly reported to have texture-related problems. Specific medicines identified with textural issues included: lactulose which was described as "oily" and co-trimoxazole liquid described as "thick and gelatinous"

12

3.4.3 Volume or Quantity

Of the medicines prescribed, 5% (29/542) were reported to have "too large" a volume or "too many" solid dosage units to be administered at one dosing interval. Volume or quantity were reported as barriers to administration for 63% (5/8) of children prescribed pancrealipase capsules, 40% (12/30) of children prescribed macrogol 3350 oral powders and 19% (3/16) of children prescribed prednisolone soluble tablets.

3.4.4 Size and aversion to or difficulty with swallowing

Problems related to i) the size of a solid dosage form or ii) aversion to or difficulty swallowing a solid dosage form was associated with 5% (28/542) of the total medicines prescribed (16% if only solid dosage forms considered).

For 16% (28/177) of solid dosage forms prescribed to patients, problems experienced either with the size of a solid dosage form or where children were averse to swallowing a solid dosage form were reported. Problems specifically related to the sizes of particular solid dosage forms were reported for 68% (19/28) of these medicines, and aversion to, or difficulty swallowing solid dosage forms was reported for the remaining 32% (9/28) of medicines. It should be noted that these patients were not physically unable to swallow (i.e. not patients fitted with an NG or PEG tube). The majority (7/8= 88%) of patients prescribed co-trimoxazole tablets reported a problem with their large size or difficulties swallowing them. These children were aged from 4 to 15 years. Although specific data on brand of formulation was not collected from parents, the size of co-trimoxazole tablets (480mg) was measured to be an average of 11mm (based on the average diameter of two different manufacturers).This could be expected based on the large amount of active ingredient within the formulation. In contrast, there were no problems reported with the size of levothyroxine tablets, owing to their significantly lower dose (micrograms) and therefore a comparatively smaller tablet.

3.4.5 Colour/appearance and smell

An unfavourable colour (descriptions provided included "alarming", off-putting, and colourless) was associated with 2% (11/542) of medicines prescribed. Two of eighteen children prescribed sodium

279 valproate liquid highlighted its "alarming colour" .. Similarly, one of nine patients prescribed

280 paracetamol liquid described its unappealing colour.

281 In addition, 2% (11/542) of medicines prescribed were identified as having "off-putting" smells. For

282 25% (2/8) of children prescribed trimethoprim liquid, an unfavourable smell was reported.

283 # 4 Discussion

284 This study has indicated that formulations prescribed to children with chronic conditions are not

285 meeting the needs of a significant number of patients based on self-report. Medicines refusal was

286 associated significantly with barriers to oral medicines administration: taste, texture,

287 quantity/volume (see Table 2). Palatability needs to be considered carefully by pharmaceutical

288 companies when designing new formulations and also by prescribers in order to optimise effective

289 prescribing, maximising adherence, therapeutic effects and reducing wastage with cost savings.

290 Other statistically significant factors associated with medicines refusal were child age at interview

291 and IMD 2010 score. Recent EMA guidance (EMA, 2013) states that age-appropriateness of

292 formulations needs to be prominent in pharmaceutical development and also when designing

293 prescribing protocols for prescribers. Further research is required to investigate the relationship

294 between socio-demographic factors and medicines refusal.

295 The formulations highlighted to be problematic are also often prescribed to treat patients with acute

296 conditions, e.g. soluble prednisolone tablets. Evaluation of the study data can inform changes in

297 prescribing practice, e.g. prescribing prednisolone tablets in preference to soluble prednisolone

298 tablets for children; even though intuitively soluble tablets are considered to be age-appropriate for

299 paediatric populations. This change has been implemented at UHCW and it is estimated that this will

300 generate a cost saving of £5000 per annum in the Paediatric Department (Personal Communication,

301 2012).

302 This study identified that almost one third (29%) of participants reported manipulating medicines.

303 Studies conducted in specific patient groups (HIV (Byrne et al., 2002; Goode et al., 2003; Wrubel et

304 al., 2005) and oncology (Christiansen et al., 2008)), reported similar findings. Several examples of

305 medicines manipulation that could affect drug bioavailability and thus therapeutic response were

306 identified and their potential physicochemical effects are reported in Table 4 below.

307

308 **Table 4: Potential physicochemical effects of medicines manipulation**

Manipulation techniques reported within this study	Potential physicochemical effects of manipulation techniques (general examples; not tested with specific formulations reported within this study)
Splitting tablets (co-trimoxazole tablets) or sachets manually (Gaviscon infant oral powders)	Inaccurate segmentation resulting in administration of inaccurate dose (underdose versus overdose)
Mixing non-soluble tablets with liquids (azathioprine tablets)	Non-uniform dosing, aggregation and sedimentation of insoluble drug particles
Crushing tablets (hydrocortisone tablets)	Thermal degradation
Mixing with foodstuffs (sodium valproate liquid)	Fruit juices (altering pH), drug binding to dairy proteins, formation of insoluble complexes

309 Limited evidence is available on the effects of mixing drugs with various foodstuffs. Prolonging the

310 contact time of a drug with a foodstuff is likely to increase the binding capability and therefore may

311 risk reducing drug bioavailability, thus affect therapeutic response. Additionally, if a drug-foodstuff

312 mixture is not consumed in its entirety, the desired dose will not be administered.

313 To minimise unnecessary medicines manipulation it is essential that prescribers consider age-

314 appropriateness, type of formulation (in relation to ease of administration), swallowing problems

315 and patient capability to swallow tablets according to size and also acceptance of different textures.

316 These factors were associated significantly with manipulation of medicines (see Table 3). The lower

317 reported refusal of solid dosage forms compared to liquids (see Table 2) may be associated with the

318 adoption of *ad hoc* manipulation techniques, and supporting this, medicines manipulation was

319 significantly associated with administering solid dosage forms (see Table 3).

320 Future formulation work needs to be implemented to develop age-appropriate formulations that are

321 accepted by children and are also available in appropriate unit doses, ideally pre-measured, covering

322 child dosing ranges and also small enough to taper doses accurately. Dosage form technologies such

15

323   as mini-tablets (Spomer et al., 2012; Thomson et al., 2009) may help to reduce the perceived need to

324   manipulate some medicines. However, it should be acknowledged that for some medicines, it may

325   be more feasible for practical and economical reasons to use safe and effective manipulation

326   techniques. Owing to the limited data available and also poor understanding of healthcare

327   professionals regarding the safety and efficacy of medicines manipulation (Akram and Mullen, 2012;

328   Venables et al., 2012) it is vital that laboratory work is conducted to provide a robust scientific

329   evidence base to support safe and effective medicines manipulation.

330   It would be useful for future studies to investigate if education to help children to learn to swallow

331   tablets could improve medicines adherence. Studies investigating infant acceptance of different

332   tastes and textures of foodstuffs (Harris, 2008; Northstone et al., 2001) agree that encouraging

333   children to accept solid dosage forms from a younger age may be beneficial. This could minimise

334   child aversion to some formulations and also reduce unnecessary modification to medication.

335   The present study is pragmatic, of multi-perspective design and has a large paediatric sample size. It

336   has expanded the pre-existing, narrowly focussed literature and identified the prevalence and

337   nature of barriers to oral medicines administration in children with chronic conditions.

338   Complementing the findings of this study, two other studies (Richey et al., 2011; Skwierczynski and

339   Conroy, 2008) identified the nature and frequency of manipulations to formulations administered to

340   children on paediatric wards. Identification of the difficulties experienced by families when

341   administering formulations to children is essential for directing future formulation development

342   work. User involvement has played a fundamental role throughout the present study.

343   A limitation within the present study is the reporting of generic formulations as opposed to specific

344   products (e.g. brands and manufacturers). This results from the nature of this pragmatic study which

345   relies upon parent/carer/patient reports. Nonetheless, this is the first study to explore barriers to

346   oral medicines administration in children with a wide range of chronic conditions. Further research is

347   required to identify whether similarly, problems are encountered with non-oral medicines and in

348   paediatric populations outside of the UK.

349   A limitation of using a self-report tool is the risk of inaccurate reporting (Butz, 2006). In this study,

350   one mother reported that medication had not been omitted, however the adolescent in her care

351   provided an opposing report. This finding reinforces the need for future studies to investigate parent

352   and teenager reports independently. In the present study, there was insufficient time and resources

353   for parents and young people to be interviewed independently and the study was designed to be

354   pragmatic, thus reflect a family environment. A study by Buchanan and co-workers (2012) found

355   significant similarity between independent reports of 'taste/cannot get it down' ($p < 0.001$),

356   forgetting ($p < 0.001$), and also refusing doses ($p = 0.01$) amongst young people with HIV and their

357   carers. These findings suggest that reporting of such outcomes is fairly consistent between carers

358   and young people, however this is only one study, conducted in children with HIV.

359   The statistical results may have been subject to confounding by other factors that were not

360   considered in the analysis and should be interpreted in light of this. However, since a range of

361   variables were considered in the analysis and a multivariable statistical approach was used,

362   confounding factors have been accounted for as far as was possible.

363 5   Conclusions

364   Almost one third (31%) of respondents reported medicines refusal on at least one occasion and 29%

365   reported manipulating formulations. Study findings indicate that oral formulations prescribed to

366   children are not suitable for a significant number of patients. Adherence and hence expected

367   therapeutic response will be potentially affected. Medicines manipulation can be a serious burden

368   for parents or carers, particularly when children are prescribed several formulations. Age-

369   appropriate formulations should be developed to provide both suitable dose units and acceptable

370   taste. Further laboratory work is required to provide robust scientific evidence to support medicines

371   manipulation techniques suitable for use in the domiciliary environment with attention to patient

372   safety and drug efficacy. In addition, prescribers and pharmacists need to be vigilant when making

373   prescribing and supply decisions respectively, to ensure that they are choosing the most appropriate

374   formulation for an individual patient.

375

379

380

381

References

Akram, G., Mullen, A.B., 2012. Paediatric nurses' knowledge and practice of mixing medication into foodstuff. International Journal of Pharmacy Practice.

Bagger-Sjöbäck, D., Bondesson, G., 1989. Taste evaluation and compliance of two paediatric formulations of phenoxymethylpenicillin in children. Scandinavian Journal of Primary Health Care 7, 87-92.

Boni, S., Pontali, E., De Gol, P., Pedemonte, P., Bassetti, D., 2000. Compliance to combination antiretroviral therapy in HIV-1 infected children. International Journal of Antimicrobial Agents 16, 371-372.

Buchanan, A.L., Montepiedra, G., Sirois, P.A., et al. 2012. Barriers to medication adherence in HIV-infected children and youth based on self-and caregiver report. Pediatrics, 129, e1244-e1251.

Butz, A., 2006. Evidence-based practice: what is the evidence for medication adherence in children? Journal of Pediatric Health Care 20, 338-341.

Byrne, M., Honig, J., Jurgrau, A., Heffernan, S., Donahue, M., 2002. Achieving adherence with antiretroviral medications for pediatric HIV disease. The AIDS reader 12, 151-154.

Chambers, R., 2000. Involving patients and the public: How to do it better, 1 ed. Radcliffe, Abingdon, Oxon.

Chan, D.S., Demers, D.M., Bass, J.W., 1997. Antimicrobial liquid formulations: A blind comparison of taste of 13 commonly prescribed medications. Journal of Pharmacy Technology 13, 206-209.

Christiansen, N., Taylor, K.M., Duggan, C., 2008. Oral chemotherapy in paediatric oncology in the UK: problems, perceptions and information needs of parents. Pharmacy World & Science 30, 550-555.

Cohen, R., de La Rocque, F., Lécuyer, A., Wollner, C., Bodin, M.J., Wollner, A., 2009. Study of the acceptability of antibiotic syrups, suspensions, and oral solutions prescribed to pediatric outpatients. European Journal of Pediatrics 168, 851-857.

Costello, I., Wong, I., Nunn, A., 2004. A literature review to identify interventions to improve the use of medicines in children. Child: care, health and development 30, 647-665.

El-Chaar, G.M., Mardy, G., Wehlou, K., Rubin, L.G., 1996. Randomized, double blind comparison of brand and generic antibiotic suspensions: II. A study of taste and compliance in children. Pediatric Infectious Disease Journal 15, 18-22.

EMA, 2013. Guideline on pharmaceutical development of medicines for paediatric use EMA/CHMP/QWP/805880/2012, London.

EMEA, 2006. Reflection paper: formulations of choice for the paediatric population EMEA/CHMP/PEG/194810/2005, London.

European Commission, 2008. Information from European Union Institutions and Bodies Commission: Communication from the Commission—Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies. Official Journal of the European Union 243, 1-12.

Gibb, D.M., Goodall, R.L., Giacomet, V., Mcgee, L., Compagnucci, A., Lyall, H., 2003. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatric Infectious Disease Journal 22, 56-62.

Gillham, B., 2000. Developing a questionnaire, 1 ed. Continuum, London.

Goode, M., McMaugh, A., Crisp, J., Wales, S., Ziegler, J.B., 2003. Adherence issues in children and adolescents receiving highly active antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV 15, 403-408.

Harris, G., 2008. Development of taste and food preferences in children. Current Opinion in Clinical Nutrition & Metabolic Care 11, 315-319.

Ingerski, L.M., Baldassano, R.N., Denson, L.A., Hommel, K.A., 2009. Barriers to Oral Medication Adherence for Adolescents with Inflammatory Bowel Disease. J. Pediatr. Psychol., jsp085.

Malim, T., Birch, A., 1996. Research methods and statistics. Macmillan, Basingstoke.

433   Marhefka, S.L., Farley, J.J., Rodrigue, J.R., Sandrik, L.L., Sleasman, J.W., Tepper, V.J., 2004. Clinical
434   assessment of medication adherence among HIV-infected children: examination of the Treatment
435   Interview Protocol (TIP). AIDS Care 16, 323-338.
436   MHRA, Medicines that do not need a licence (Exemptions from licensing): The manufacture and
437   supply of unlicensed relevant medicinal products for individual patients ('specials').
438   Morisky, D.E., Ang, A., Krousel-Wood, M., Ward, H.J., 2008. Predictive Validity of A Medication
439   Adherence Measure in an Outpatient Setting. Journal of Clinical Hypertension 10 348-354.
440   Morisky, D.E., Green, L.W., Levine, D.M., 1986. Concurrent and predictive validity of a self-reported
441   measure of medication adherence. Medical Care 24, 67-74.
442   NIAID, PEDIATRIC AIDS CLINICAL TRIALS GROUP (PACTG) Pediatric adherence questionnaire: module
443   2 General reasons for non-adherence QL5001.
444   Northstone, K., Emmett, P., Nethersole, F., 2001. The effect of age of introduction to lumpy solids on
445   foods eaten and reported feeding difficulties at 6 and 15 months. Journal of Human Nutrition and
446   Dietetics 14, 43-54.
447   Pontali, E., Feasi, M., Toscanini, F., Bassetti, M., De Gol, P., Nuzzolese, A., Bassetti, D., 2001.
448   Adherence to combination antiretroviral treatment in children. HIV Clinical Trials 2, 466-473.
449   Pope, C., Ziebland, S., Mays, N., 2000. Analysing qualitative data. Bmj 320, 114-116.
450   Richey, R., Donnell, C., Shah, U., Barker, C., Craig, J., Ford, J., Peak, M., Turner, M., Nunn, A., 2011. An
451   investigation of drug manipulation for dose accuracy in paediatric practice: the modric study.
452   Archives of Disease in Childhood 96, e1-e1.
453   Salunke, S., Hempenstall, J., Kendall, R., Rogerd, B., Mroze, C., Nunn, T., Tuleu., 2011. European
454   Paediatric Formulation Initiative's (EuPFI) 2nd conference commentary—Formulating better
455   medicines for children. International Journal of Pharmaceutics 419, 235-239.
456   Samulak, K.M., El-Chaar, G.M., Rubin, L.G., 1996. Randomized, double blind comparison of brand and
457   generic antibiotic suspensions: I. A study of taste in adults. Pediatric Infectious Disease Journal 15,
458   14-17.
459   Skwierczynski, C., Conroy, S., 2008. How long does it take to administer oral medicines to children?
460   Paediatric and Perinatal Drug Therapy 8, 145-149.
461   Spomer, N., Klingmann, V., Stoltenberg, I., Lerch, C., Meissner, T., Breitkreutz, J., 2012. Acceptance of
462   uncoated mini-tablets in young children: results from a prospective exploratory cross-over study.
463   Archives of Disease in Childhood 97, 283-286.
464   Thomson, S.A., Tuleu, C., Wong, I.C.K., Keady, S., Pitt, K.G., Sutcliffe, A.G., 2009. Minitablets: new
465   modality to deliver medicines to preschool-aged children. Pediatrics 123, e235-238.
466   Toscani, M., Drehobl, M., Freed, J., Stool, S., 2000. A multicenter, randomized, comparative
467   assessment in healthy pediatric volunteers of the palatability of oral antibiotics effective in the
468   therapy of otitis media. Current Therapeutic Research - Clinical and Experimental 61, 278-285.
469   Venables, R., Marriott, J., Stirling, H., 2012. Find out: Healthcare professionals' perceptions of
470   problems with paediatric formulations: A focus group study. International Journal of Pharmacy
471   Practice Conference, Royal Pharmaceutical Society, RPS Annual Conference 2012 Birmingham United
472   Kingdom.
473   Winnick, S., Lucas, D.O., Hartman, A.L., Toll, D., 2005. How do you improve compliance? Pediatrics
474   115, e718-724.
475   Wrubel, J., Tedlie Moskowitz, J., Anne Richards, T., Prakke, H., Acree, M., Folkman, S., 2005. Pediatric
476   adherence: Perspectives of mothers of children with HIV. Social Science & Medicine 61, 2423-2433.
477   Zelikovsky, N., Schast, A.P., Palmer, J.A., Meyers, K.E.C., 2008. Perceived barriers to adherence
478   among adolescent renal transplant candidates. Pediatric Transplantation 12, 300-308.

479

480